AXSM Axsome Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AXSM

Price (delayed)

$67.45

Market cap

$3.19B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.55

Enterprise value

$2.96B

Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people ...

Highlights
The revenue has grown by 22% from the previous quarter
AXSM's gross profit is up by 22% since the previous quarter
The equity has surged by 71% year-on-year but it has declined by 3.3% since the previous quarter
Axsome Therapeutics's debt has surged by 97% YoY
The net income has contracted by 26% YoY and by 9% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.axsome.com
Peers: OMGA

Key stats

What are the main financial stats of AXSM
Market
Shares outstanding
47.32M
Market cap
$3.19B
Enterprise value
$2.96B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
11.81
Price to sales (P/S)
14.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.25
Earnings
Revenue
$223.44M
EBIT
-$193.47M
EBITDA
-$185.24M
Free cash flow
-$143.04M
Per share
EPS
-$4.55
Free cash flow per share
-$3.04
Book value per share
$5.71
Revenue per share
$4.74
TBVPS
$11.33
Balance sheet
Total assets
$600.86M
Total liabilities
$331.35M
Debt
$185.58M
Equity
$269.51M
Working capital
$397.1M
Liquidity
Debt to equity
0.69
Current ratio
4.46
Quick ratio
4.32
Net debt/EBITDA
1.25
Margins
EBITDA margin
-82.9%
Gross margin
90.6%
Net margin
-90.3%
Operating margin
-86.6%
Efficiency
Return on assets
-41.8%
Return on equity
-104.9%
Return on invested capital
-142.2%
Return on capital employed
-39.8%
Return on sales
-86.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AXSM stock price

How has the Axsome Therapeutics stock price performed over time
Intraday
0.9%
1 week
12.23%
1 month
12.36%
1 year
-6.7%
YTD
-12.55%
QTD
-3.49%

Financial performance

How have Axsome Therapeutics's revenue and profit performed over time
Revenue
$223.44M
Gross profit
$202.46M
Operating income
-$193.47M
Net income
-$201.83M
Gross margin
90.6%
Net margin
-90.3%
Axsome Therapeutics's net margin has surged by 86% YoY and by 11% QoQ
AXSM's operating margin has soared by 85% year-on-year and by 9% since the previous quarter
The company's operating income fell by 27% YoY and by 11% QoQ
The net income has contracted by 26% YoY and by 9% from the previous quarter

Growth

What is Axsome Therapeutics's growth rate over time

Valuation

What is Axsome Therapeutics stock price valuation
P/E
N/A
P/B
11.81
P/S
14.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.25
The EPS has contracted by 12% YoY and by 6% from the previous quarter
The P/B is 71% lower than the 5-year quarterly average of 41.4 and 39% lower than the last 4 quarters average of 19.5
The equity has surged by 71% year-on-year but it has declined by 3.3% since the previous quarter
The price to sales (P/S) is 50% lower than the last 4 quarters average of 28.3
The revenue has grown by 22% from the previous quarter

Efficiency

How efficient is Axsome Therapeutics business performance
The ROS has soared by 85% YoY and by 9% from the previous quarter
The ROE has soared by 67% YoY and by 7% from the previous quarter
AXSM's ROA has soared by 55% YoY and by 5% QoQ
The company's return on invested capital has surged by 50% YoY and by 12% QoQ

Dividends

What is AXSM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AXSM.

Financial health

How did Axsome Therapeutics financials performed over time
Axsome Therapeutics's total assets is 81% more than its total liabilities
AXSM's total liabilities has soared by 82% year-on-year
Axsome Therapeutics's total assets has soared by 77% YoY
Axsome Therapeutics's debt is 31% lower than its equity
Axsome Therapeutics's debt has surged by 97% YoY
The equity has surged by 71% year-on-year but it has declined by 3.3% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.